Jivi

Procedural steps taken and scientific information after the authorisation

Application number	Scope	Opinion/ Notification [1] issued on	Commission Decision Issued [2] / amended on	Product Information affected [3]	Summary
II/0034	Extension of indication to include treatment and prophylaxis of bleeding in previously treated patients ≥7 years of age with haemophilia A for Jivi, based on integrated analysis results from Part A of the Alfa-PROTECT study (21824) and PROTECT Kids main study (15912). Alfa-PROTECT is a Phase 3, single-	25/04/2025	02/06/2025	SmPC, Annex II, Labelling and PL	Please refer to Scientific Discussion 'Jivi-H-C-004054-II-34'

[1] Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.
[2] A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.
[3] SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

	group treatment, open-label study to evaluate the safety of BAY 94-9027 infusions for prophylaxis and treatment of bleeding in previously treated children aged 7 to <12 years with severe haemophilia A. PROTECT Kids is a multi-center, Phase 3, non-controlled, open-label trial to evaluate the pharmacokinetics, safety, and efficacy of BAY 94-9027 for prophylaxis and treatment of bleeding in previously treated children (age <12 years) with severe haemophilia A. As a consequence, sections 2, 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 3.3 of the RMP has also been submitted. In addition, the Marketing authorisation holder (MAH) took the opportunity to update the list of local representatives in the Package Leaflet. Furthermore, the PI is brought in line with the latest QRD template version 10.4. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one				
IB/0032/G	This was an application for a group of variations. B.I.d.1.b.1 - Stability of AS - Change in the storage conditions - Change to more restrictive storage conditions of the AS B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.4.b - Change to in-process tests or limits	05/09/2024	n/a		

	applied during the manufacture of the AS - Addition of a new in-process test and limits				
II/0031/G	This was an application for a group of variations. B.I.b.1.f - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Change outside the approved specifications limits range for the AS B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate	11/04/2024	n/a		
PSUSA/10732 /202308	Periodic Safety Update EU Single assessment - damoctocog alfa pegol	11/04/2024	n/a		PRAC Recommendation - maintenance
II/0028	C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority	28/09/2023	n/a		
IB/0029	B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)	25/09/2023	n/a		

R/0027	Renewal of the marketing authorisation.	26/04/2023	23/06/2023	SmPC, Annex II, Labelling and PL	Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Jivi in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity.
II/0025/G	This was an application for a group of variations. B.II.b.1.f - Replacement or addition of a manufacturing site for part or all of the manufacturing process of the FP - Site where any manufacturing operation(s) take place, except batch release, batch control, and secondary packaging, for sterile medicinal products (including those that are aseptically manufactured) excluding biological/ immunological medicinal products B.II.e.1.b.2 - Change in immediate packaging of the finished product - Change in type/addition of a new container - Sterile medicinal products and biological/immunological medicinal products	17/11/2022	n/a		
II/0024/G	This was an application for a group of variations. B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a biological AS B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement	17/11/2022	n/a		

	or addition) for the AS or a starting material/intermediate B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a biological AS B.I.b.1.f - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Change outside the approved specifications limits range for the AS B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a biological AS B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition) B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a biological AS B.II.d.1.e - Change in the specification parameters and/or limits of the finished product - Change				

	outside the approved specifications limits range				
IB/0026	B.II.z - Quality change - Finished product - Other variation	03/10/2022	n/a		
II/0023	B.II.e.1.b.2 - Change in immediate packaging of the finished product - Change in type/addition of a new container - Sterile medicinal products and biological/immunological medicinal products	30/06/2022	n/a		
II/0019/G	This was an application for a group of variations. B.I.b.1.f - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Change outside the approved specifications limits range for the AS B.II.d.1.e - Change in the specification parameters and/or limits of the finished product - Change outside the approved specifications limits range	22/04/2022	n/a		
PSUSA/10732 /202108	Periodic Safety Update EU Single assessment - damoctocog alfa pegol	07/04/2022	n/a		PRAC Recommendation - maintenance
IB/0022	B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation	24/11/2021	n/a		
N/0020	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	20/10/2021	23/06/2023	PL	
IB/0018	C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing	22/07/2021	n/a		

	authorisation, including the RMP - Other variation				
PSUSA/10732 /202008	Periodic Safety Update EU Single assessment - damoctocog alfa pegol	09/04/2021	n/a		PRAC Recommendation - maintenance
II/0017	Submission of the final report from the pharmacokinetic study 19742 comparing the pharmacokinetic parameters of Jivi vs. Adynovi. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority	18/03/2021	n/a		Submission of the final report from the pharmacokinetic study 19742 comparing the pharmacokinetic parameters of Jivi vs. Adynovi. Results of the study did not change the PK profile or benefit/risk assessment for Jivi, therefore no change of the Jivi SmPC is needed. Please refer to Scientific Discussion 'Product Name-H-C-Product Number-II-Var.No'
II/0015	Update of sections 4.8 and 5.1 of the SmPC to reflect the final study report of the long-term extension study 15912 (PROTECT Kids) in children. This extension study is a category 3 study of the Jivi RMP. The MAH took the oportunity to update the list of local representatives in the PIL. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data	12/11/2020	18/12/2020	SmPC and PL	SmPC new text As a result of this variation, sections 4.8 and 5.1 of the SmPC were updated to include the following: Section 4.8: "In the paediatric study, 59/73 patients < 12 years continued in the extension study. Median (range) total time in study (main study + extension) was 5.8 (1.0-6.6) years with a median of 430 (range 98-671) ED per subject, 39 subjects were treated for =/> 5 years. The median number of exposure days to Jivi per subject was 95237 (min-max: 1-698) for all subjects in the clinical studies. Overall, in both studies 75 patients were observed for a treatment duration of more than 5 years." Section 5.1: "For 59 patients who continued in the extension study the overall median (Q1;Q3) ABR during the extension period was 1.64 (0.5, 3.1). For 30 patients ≥ 12 years at the end of the extension study, the median (Q1; Q3) ABR was 1.76 (0.5; 3.3)," which is in accordance with the presented results in the final study report and thus

					accepted. For more information, please refer to the Summary of Product Characteristics.
PSUSA/10732 /202002	Periodic Safety Update EU Single assessment - damoctocog alfa pegol	01/10/2020	n/a		PRAC Recommendation - maintenance
II/0014	Addition of the following additional site for quality control testing of the drug product in the US: Bayer HealthCare LLC, 800 Dwight Way, Berkeley, CA 94710 (USA). B.II.b.2.b - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place for a biol/immunol product and any of the test methods at the site is a biol/immunol method	10/09/2020	n/a		
II/0012	Update of sections 4.8 and 5.1 of the SmPC to reflect the final study results of the long-term extension study 13024 (PROTECT VIII). This extension study is a category 3 study of the Jivi RMP (MEA-005). The PL is updated to reflect a change in the contact of a local representative. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data	03/09/2020	18/12/2020	SmPC and PL	
IAIN/0013	C.I.11.a - Introduction of, or change(s) to, the obligations and conditions of a marketing	31/07/2020	n/a		

	authorisation, including the RMP - Implementation of wording agreed by the competent authority				
PSUSA/10732 /201908	Periodic Safety Update EU Single assessment - damoctocog alfa pegol	12/03/2020	n/a		PRAC Recommendation - maintenance
II/0004	C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority	06/02/2020	n/a		
IAIN/0010	C.I.11.a - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of wording agreed by the competent authority	04/02/2020	n/a		
IB/0008/G	This was an application for a group of variations. B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside	20/12/2019	18/12/2020	SmPC, Annex II, Labelling and PL	

	the range of the currently approved pack sizes B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes				
IA/0009/G	This was an application for a group of variations. B.I.a.4.a - Change to in-process tests or limits applied during the manufacture of the AS - Tightening of in-process limits B.III.2.a.2 - Change of specification(s) of a former non EU Pharmacopoeial substance to fully comply with the Ph. Eur. or with a national pharmacopoeia of a Member State - Excipient/AS starting material B.III.2.a.2 - Change of specification(s) of a former non EU Pharmacopoeial substance to fully comply with the Ph. Eur. or with a national pharmacopoeia of a Member State - Excipient/AS starting material	12/12/2019	n/a		
IAIN/0006	B.IV.1.a.1 - Change of a measuring or administration device - Addition or replacement of a device which is not an integrated part of the primary packaging - Device with CE marking	25/10/2019	n/a		
IA/0005	B.II.f.1.e - Stability of FP - Change to an approved stability protocol	15/10/2019	n/a		
PSUSA/10732 /201902	Periodic Safety Update EU Single assessment - damoctocog alfa pegol	03/10/2019	n/a		PRAC Recommendation - maintenance

IA/0002	B.II.e.7.a - Change in supplier of packaging components or devices (when mentioned in the dossier) - Deletion of a supplier	28/03/2019	n/a		
II/0001	C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority	14/02/2019	n/a		